Ulrike Leiter1, Rudolf Stadler2, Cornelia Mauch3, Werner Hohenberger4, Norbert H Brockmeyer2, Carola Berking5, Cord Sunderkötter6,7, Martin Kaatz8,9, Kerstin Schatton10, Percy Lehmann11, Thomas Vogt12, Jens Ulrich13, Rudolf Herbst14, Wolfgang Gehring15, Jan-Christoph Simon16, Ulrike Keim1, Danielle Verver17, Peter Martus1, Claus Garbe1. 1. Eberhard Karls University of Tübingen, Tübingen, Germany. 2. Ruhr University Bochum, Bochum, Germany. 3. University of Köln/Bonn, Cologne, Germany. 4. University of Erlangen, Erlangen, Germany. 5. Ludwig-Maximilians University, Munich, Germany. 6. University of Munster, Munster, Germany. 7. University Hospital Halle, Halle, Germany. 8. SRH Wald-Klinikum Gera, Gera, Germany. 9. University of Jena, Jena, Germany. 10. University of Düsseldorf, Dusseldorf, Germany. 11. HELIOS-Klinikum Wuppertal, Wuppertal, Germany. 12. University of Homburg, Homburg, Germany. 13. University of Magdeburg, Quedlinburg, Germany. 14. HELIOS-Klinikum Erfurt, Erfurt, Germany. 15. Carl Von Ossietzky University, Oldenburg, Germany. 16. University of Leipzig, Leipzig, Germany. 17. Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Abstract
PURPOSE: We have previously reported on the 3-year results of the phase III German Dermatologic Cooperative Oncology Group trial (DeCOG; ClinicalTrials.gov identifier: NCT02434107) comparing distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and overall survival (OS) in patients with positive sentinel lymph-node biopsy who were randomly assigned to complete lymph node dissection (CLND) or observation. Here, we report the final analysis with 72 months of median follow up. PATIENTS AND METHODS: The multicenter randomized phase III trial included patients with cutaneous melanoma of the trunk and extremities who were randomly assigned (1:1) to undergoCLND or observation. DMFS was analyzed as the primary end point, and RFS, OS, and recurrences in the regional lymph node basin were secondary end points. The analysis was by intention to treat. Disease and survival information were collected quarterly. RESULTS:From January 2006 to December 2014, 5,547 patients were screened to identify 1,256 with metastases in the sentinel lymph node (SLN). Of these, 483 (39%) were included: 241 in the observation arm and 242 in the CLND arm. In the final analysis, median follow up was 72 months (interquartile range, 67-77 months). No significant treatment-related difference was seen in the 5-year DMFS between the observation and CLND arms (67.6% v 64.9%, respectively; hazard ratio [HR], 1.08; P = .87). The 5-year RFS and OS also showed no difference (HR, 1.01 and 0.99, respectively). Grade 3 and 4 adverse effects occurred in 32 patients (13%) in the CLND arm; lymphedema (n = 20) and delayed wound healing (n = 5) were most common and no serious adverse events were reported. CONCLUSION: The final results of the German Dermatologic Cooperative Oncology Group trial with a median follow up of 72 months showed higher event rates, but similar HRs compared with those at the 3-year analysis. These results confirm that immediate CLND in SLN-positive patients is not superior to observation in terms of DMFS, RFS, or OS and support not recommending CLND in patients with SLN metastasis.
RCT Entities:
PURPOSE: We have previously reported on the 3-year results of the phase III German Dermatologic Cooperative Oncology Group trial (DeCOG; ClinicalTrials.gov identifier: NCT02434107) comparing distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and overall survival (OS) in patients with positive sentinel lymph-node biopsy who were randomly assigned to complete lymph node dissection (CLND) or observation. Here, we report the final analysis with 72 months of median follow up. PATIENTS AND METHODS: The multicenter randomized phase III trial included patients with cutaneous melanoma of the trunk and extremities who were randomly assigned (1:1) to undergo CLND or observation. DMFS was analyzed as the primary end point, and RFS, OS, and recurrences in the regional lymph node basin were secondary end points. The analysis was by intention to treat. Disease and survival information were collected quarterly. RESULTS: From January 2006 to December 2014, 5,547 patients were screened to identify 1,256 with metastases in the sentinel lymph node (SLN). Of these, 483 (39%) were included: 241 in the observation arm and 242 in the CLND arm. In the final analysis, median follow up was 72 months (interquartile range, 67-77 months). No significant treatment-related difference was seen in the 5-year DMFS between the observation and CLND arms (67.6% v 64.9%, respectively; hazard ratio [HR], 1.08; P = .87). The 5-year RFS and OS also showed no difference (HR, 1.01 and 0.99, respectively). Grade 3 and 4 adverse effects occurred in 32 patients (13%) in the CLND arm; lymphedema (n = 20) and delayed wound healing (n = 5) were most common and no serious adverse events were reported. CONCLUSION: The final results of the German Dermatologic Cooperative Oncology Group trial with a median follow up of 72 months showed higher event rates, but similar HRs compared with those at the 3-year analysis. These results confirm that immediate CLND in SLN-positive patients is not superior to observation in terms of DMFS, RFS, or OS and support not recommending CLND in patients with SLN metastasis.
Authors: Daan Jan Willem Rauwerdink; George Molina; Dennie Tompers Frederick; Tanya Sharova; Harrison Carmichael; Genevieve Marie Boland Journal: Ann Surg Oncol Date: 2020-05-23 Impact factor: 5.344
Authors: Hayley Standage; Alyssa R Hersh; Aaron Caughey; Matthew Taylor; John Vetto; Dale Han Journal: Ann Surg Oncol Date: 2020-09-19 Impact factor: 5.344
Authors: Brooke C Bredbeck; Eman Mubarak; Daniela G Zubieta; Rachael Tesorero; Adam R Holmes; Lesly A Dossett; Kyle K VanKoevering; Alison B Durham; Tasha M Hughes Journal: J Surg Oncol Date: 2020-09-06 Impact factor: 3.454
Authors: Devarati Mitra; Gabriel Ologun; Emily Z Keung; Ryan P Goepfert; Rodabe N Amaria; Merrick I Ross; Jeffrey E Gershenwald; Anthony Lucci; Sarah B Fisher; Michael A Davies; Jeffrey E Lee; Andrew J Bishop; Ahsan S Farooqi; Jennifer Wargo; B Ashleigh Guadagnolo Journal: Ann Surg Oncol Date: 2021-04-15 Impact factor: 5.344
Authors: Kristy K Broman; Deepti Bettampadi; Jaileene Pérez-Morales; James Sun; Dennis Kirichenko; Michael J Carr; Zeynep Eroglu; Ahmad A Tarhini; Nikhil Khushalani; Matthew B Schabath; Amod Sarnaik; Vernon K Sondak; Jonathan S Zager Journal: Ann Surg Oncol Date: 2021-08-06 Impact factor: 5.344